UK neurologists release new guidelines for JC virus testing in patients using the natalizumab biosimilar Tyruko, addressing ...
FDA's new guidance streamlines biosimilar development, reducing costs and regulatory hurdles and potentially enhancing market ...
A recent study reveals global regulatory inconsistencies in biosimilars, urging convergence to enhance access and savings for patients and health care systems.
The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and ...
A new study confirms that biosimilar ranibizumab matches innovator Lucentis in treating myopic choroidal neovascular membrane ...
Biosimilars revolutionize health care access in Latin America, offering cost savings and improved treatment availability for ...
A recent study confirms the stability of XSB-001 biosimilar for retinal diseases under realistic clinical handling conditions. Ranibizumab, an anti–vascular endothelial growth factor (VEGF)–A fragment ...
A new study reveals Stivant, a bevacizumab biosimilar, matches Avastin in safety and efficacy for treating retinopathy of prematurity in infants. Stivant, demonstrated similar efficacy and safety to ...
The FDA has approved Celltrion's Eydenzelt, a new aflibercept biosimilar, enhancing treatment options for retinal diseases in the US. The FDA has approved Eydenzelt (aflibercept-boav), an aflibercept ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback